Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer

Drugs

Volumn 72, Issue SUPPL. 1, 2012, Pages 28-36

  Califano, Raffaele ^a   Landi, Lorenza ^b   Cappuzzo, Federico ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b Livorno Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; METMAB; MONOCLONAL ANTIBODY; NAVELBINE; PANITUMUMAB; PLACEBO; TAXANE DERIVATIVE; TIVANTINIB; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FEBRILE NEUTROPENIA; GENE MUTATION; HAZARD RATIO; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOG RANK TEST; LUNG BIOPSY; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; TUMOR BIOPSY; WILD TYPE;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; GENES, RAS; HUMANS; LUNG NEOPLASMS; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84862571677     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/1163012-S0-000000000-00000     Document Type: Review

References (51)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009 Jul 1; 59 (4): 225-49
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 Jun 4; 304 (5676): 1497-500 (Pubitemid 38720929)
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20; 350 (21): 2129-39 (Pubitemid 38637993)
4. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U~A 2004 Sep 7; 101 (36): 13306-11
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 Sep 3; 361 (10): 947-57
6. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11 (2): 121-8
7. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or Chemotherapy for Non Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med 2010; 362 (25): 2380-8
8. Lee DH, Park K, Kim JH, et al. Randomized Phase III Trial of Gefitinib versus Docetaxel in Non Small Cell Lung Cancer Patients Who Have Previously Received Platinum- Based Chemotherapy. Clin Cancer Res 2010 Feb 15; 16 (4): 1307-14
9. Zhou C, Wu Y-L, Chen G, et al. Efficay results from the randomised phase II OPTIMAL (CTNOG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR activating mutation. Ann Oncol 2010 Oct; 21 Suppl. 8: viii5
10. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11 (6): 521-9
11. Shepherd FA, Douillard J, Fukuoka M, et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. ASCO Meeting Abstracts 2009 Jun 8; 27 (15S): 8011
12. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. The Lancet 2008 Nov 28; 372 (9652): 1809-18
13. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non Small-Cell Lung Cancer. J Clin Oncol 2008 Sep 10; 26 (26): 4244-52
14. Cufer T, Vrdoljak E, Gaafar R, et al., group obotSs. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anti-Cancer Drugs 2006; 17 (4): 401-9 10.1097/01.cad.0000203381.99490.ab (Pubitemid 44309982)
15. Dahabreh IJ, Terasawa T, Castaldi PJ, et al. Systematic Review: Anti Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer. Ann Intern Med 2011 Jan 4; 154 (1): 37-49
16. Bos JL. ras Oncogenes in Human Cancer: A Review. Cancer Res 1989 Sep 1; 49 (17): 4682-9 (Pubitemid 19213607)
17. Rodenhuis S, van de Wetering ML, Mooi WJ, et al. Mutational Activation of the K-ras Oncogene. N Engl J Med 1987; 317 (15): 929-35
18. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008 Mar 1; 58 (2): 71-96 (Pubitemid 351521864)
19. Forbes S, Clements J, Dawson E, et al. COSMIC 2005. Br J Cancer 2006; 94 (2): 318-22 (Pubitemid 43151554)
20. Riely GJ, Kris MG, Marks JL, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. ASCO Meeting Abstracts 2008 Aug 18; 26 (15 Suppl.): 8006
21. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990 Aug 30; 323 (9): 561-5 (Pubitemid 20260082)
22. Nelson HH, Christiani DC, Mark EJ, et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999 Dec 1; 91 (23): 2032-8
23. Lu C, Soria JC, Tang X, et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 2004 Nov 15; 22 (22): 4575-83 (Pubitemid 41185125)
24. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008 Feb; 3 (2): 111-16 (Pubitemid 351323183)
25. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005 Jan 17; 92 (1): 131-9 (Pubitemid 40188446)
26. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus Cisplatin vs. Observation in Resected Non Small-Cell Lung Cancer. N Engl J Med 2005; 352 (25): 2589-97 (Pubitemid 41007845)
27. Tsao M, Hainaut P, Bourredjem A, et al. LACE-BIO pooled analysis of the prognostic and predictive value of kras mutation in completely resected non-small cell lung cancer (NSCLC). Ann Oncol 2010 Oct; 21 Suppl. 8: viii63
28. Camps C, Jantus-Lewintre E, Cabrera A, et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer 2011 Jun; 72 (3): 365-9
29. Kalikaki A, Koutsopoulos A, Hatzidaki D, et al. Clinical outcome of patientswith non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS-mutation status. Lung Cancer 2010 Jul; 69 (1): 110-5
30. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006 Oct 15; 12 (20 Pt 1): 6049-55 (Pubitemid 44703768)
31. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007 Mar 1; 25 (7): 760-6 (Pubitemid 350002874)
32. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005 Mar; 2 (3): e73
33. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007 May 15; 13 (10): 2890-6 (Pubitemid 46849563)
34. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9 (10): 962-72
35. Mao C, Qiu L-X, Liao R-Y, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer 2009; 69 (3): 272-8
36. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 Jul 14; 353 (2): 123-32 (Pubitemid 41058344)
37. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005 Sep 1; 23 (25): 5900-9
38. Zhu C-Q, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008 Sep 10; 26 (26): 4268-75
39. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011 Aug; 12 (8): 795-805
40. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non Small-Cell Lung Cancer. J Clin Oncol 2010 Feb 20; 28 (6): 918-27
41. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. ASCO Meeting Abstracts 2011 Jun 9; 29 (15 Suppl.): 7505
42. Sequist L, Akerley W, Brugger W, et al. Final results from ARQ197-209: A global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naive patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2010 Oct; 21 Suppl. 8: viii122
43. Miller VA, O'Connor P, Soh C, et al., for the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2009 Jun 18; 27 (18S): LBA8002
44. Douillard J-Y, Shepherd FA, Hirsh V, et al. Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial. J Clin Oncol 2010 Feb 10; 28 (5): 744-52
45. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009 May 2; 373 (9674): 1525-31
46. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non, Äì Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099. J Clin Oncol 2010 Feb 20; 28 (6): 911-17
47. Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005 Aug 17; 97 (16): 1185-94 (Pubitemid 41258224)
48. Danenberg KD, Grimminger PP, Mack PC, et al. KRAS mutations (MTs) in non-small cell lung cancer (NSCLC) versus colorectal cancer (CRC): Implications for cetuximab therapy. ASCO Meeting Abstracts 2010 Jun 14; 28 (15 Suppl.): 10529
49. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003 May 1; 21 (9): 1760-6 (Pubitemid 46638589)
50. Evans TL, Fidias P, Skarin A, et al. A phase II study of efficacy and tolerability of the farnesyl-protein transferase inhibitor L-778,123 as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 2002 (abstr 1861)
51. Kim ES, Kies MS, Fossella FV, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 2005; 104 (3): 561-9 (Pubitemid 41022814)